Current EU procurement rules that focus on reducing the costs of acquiring medicines have led to the consolidation of supply and increased risk for supply security, said Medicines for Europe in its latest position paper.
As such, the European organization for the generic, biosimilar, and value-added medicines industries has explored the reasons and ways to restructure the current design of off-patent medicines procurement